2016 American Transplant Congress
Quantiferon-CMV Test, CMV-Specific ELISPOT and CMV-Dextramer Assays in Assessing the Risk of CMV Infection in Seropositive Kidney Transplant Recipients.
Human cytomegalovirus (CMV) infection is one of the primary opportunistic pathogens and is a leading cause of morbidity and mortality in kidney transplant recipients. Assessing…2016 American Transplant Congress
Evaluation of a Novel Global Immunity Assay to Predict Infections in Organ Transplant Recipients.
Multi-Organ Transplant, University Health Network, Toronto, Canada.
BackgroundSimple standardized measures of global immunity may help predict the risk of infections post-transplant. The Quantiferon-Monitor (QFM) test is a novel interferon-γ (IFN-γ) release assay…2015 American Transplant Congress
Low Dose Valganciclovir Is an Effective Prophylaxis Against Cytomegalovirus in High Risk (Donor+/ Recipient-) Kidney Transplants Recipients
Introduction: Universal prophylaxis against Cytomegalovirus (CMV) disease is endorsed in high risk seronegative kidney (K) transplant (TX) recipients of organs from seropositive donors (D+/R-) using…2015 American Transplant Congress
Preemptive Therapy for Cytomegalovirus Disease in Liver Transplant Recipients-A Single Center Experience
1Rush University Medical Center, Chicago, IL; 2Lahey Hospital and Medical Center, Boston, MA.
Background: Cytomegalovirus (CMV) is a common opportunistic infection after liver transplantation and is associated with significant morbidity and mortality. There are two strategies for preventing…2015 American Transplant Congress
Role of CMV, BKV, and Immunosupression Non-Adherence in Early and Late De Novo Donor Specific Anti-HLA Antibody Development and Outcomes
This analysis aims to identify appropriate de novo DSA (dnDSA) screening points and delineate the post-transplant (txp) scenarios preceding dnDSA development to aid in clinical…2015 American Transplant Congress
Low Dose Valganciclovir Prophylaxis Following Renal Transplantation With Steroid Free Immunosuppression
AST ID guidelines recommend a valganciclovir (VGCV) prophylaxis dose of 900 mg daily for patients with CrCL > 60 mL/min with reduced dose for renal…2015 American Transplant Congress
Impact of Anti-CMV Prophylactic Therapy on the Development of CMV Quantiferon Sero-Conversion in High-Risk Patients
Transplant Surgery, Medical University of South Carolina, Charleston, SC.
Body: Abdominal organ transplants at high risk for CMV infection (D+/R) remain a difficult cohort to prevent late CMV infection despite prolonged valganciclovir (VGC) administration.…2015 American Transplant Congress
Does Prophylaxis Strategy Matter? CMV Reactivation in Moderate Risk (R+) Heart Transplant Recipients
Pharmacy, Tampa General Hospital, Tampa, FL.
Purpose: CMV is a significant complication in heart transplant recipients (HTR). Little evidence exists to guide prophylaxis in moderate risk (R+) patients.Methods: An IRB-approved review…2015 American Transplant Congress
Invasive CMV-Infection of the Duodenal Cuff – An Underestimated Entity of CMV Infection and Its Potential Impact On Outcome After Pancreas Transplantation
IntroductionWe present data on the incidence of focal invasive CMV-infection of the duodenal cuff and its potential impact on clinical outcome after pancreas transplantation (PT).Material…2015 American Transplant Congress
The Impact of Administrating Everolimus Before Cytomegalovirus Infection to Prevent CMV Recurrence in Heart Transplant Recipients
Cardiovascular Surgery, Osaka University, Suita, Osaka, Japan.
Purpose – Cytomegalovirus (CMV) infection is a major complication in heart transplant recipients. Recent trials indicate that the use of the mammalian target of rapamycin…
- « Previous Page
- 1
- …
- 28
- 29
- 30
- 31
- 32
- 33
- Next Page »